As of Wednesday close, CureVac N.V.’s (NASDAQ:CVAC) stock was up $0.16, moving up 1.73 percent to $9.41. The average number of shares traded per day over the past five days has been 425,120 shares. 5 times new highs have been achieved over the past 5 days, with a $0.62 gain in that time frame. In the last twenty days, the average volume was 381,560, while in the previous 50 days, it was 655,634.
Since last month, CVAC stock retreated -3.78%. Shares of the company fell to $8.07 on 07/28/23, the lowest level in the past month. A 52-week high of $13.82 was reached on 01/11/23 after having rallying from a 52-week low of $5.63. Since the beginning of this year, CVAC’s stock price has risen by 56.05% or $3.38, and marked a new high 5 times. However, the stock has declined by -31.91% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 2.73. Besides these, the trailing price-to-sales (P/S) ratio of 37.84, the price-to-book (PB) ratio of 2.56.
Financial Health
In the three months ended March 30, CureVac N.V.’s quick ratio stood at 7.30, while its current ratio was 7.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.05, and the total debt-to-equity ratio was 0.06. Based on annual data, CVAC earned -$122.82 million in gross profit and brought in $71.03 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -43.30%. Return on equity (ROE) for the past 12 months was -46.70%.
In CureVac N.V.’s quarter-end financial report for March 30, it reported total debt of $0.32 million. CVAC’s revenue rose 100.0% during the quarter, while net income inched up to $54.74 million. While analysts expected CureVac N.V. to report -$0.37 quarterly earnings, the actual figure was -$0.3 per share, beating the consensus estimate by 18.90%. During the quarter, the company generated -$58.5 million in EBITDA. The liabilities of CureVac N.V. were 279.38 million at the end of its most recent quarter ended March 30, and its total debt was $41.15 million.
Technical Picture
This quick technical analysis looks at CureVac N.V.’s (CVAC) price momentum. With a historical volatility rate of 37.87%, the RSI 9-day stood at 59.48% on 16 August.
With respect to its five-day moving average, the current CureVac N.V. price is up by +7.05% percent or $0.62. At present, CVAC shares trade -5.81% below its 20-day simple moving average and +44.10% percent above its 100-day simple moving average. However, the stock is currently trading approximately -0.53% below its SMA50 and +25.30% above its SMA200.
Stochastic coefficient K was 81.84% and Stochastic coefficient D was 79.87%, while ATR was 0.53. Given the Stochastic reading of 64.73% for the 14-day period, the RSI (14) reading has been calculated as 52.88%. As of today, the MACD Oscillator reading stands at 0.36, while the 14-day reading stands at 0.34.
Analyst Ratings
SVB Securities launched its rating on CureVac N.V. (NASDAQ: CVAC) to an Outperform in a note to investors on June 08, 2023. CureVac N.V. (CVAC) has been rated Overweight by analysts. According to 0 brokerage firms, CVAC is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate CureVac N.V. stock as buy, with 6 recommending it as overweight.
With a median target price of $16.62, the current consensus forecast for the stock is $9.11 – $20.86. Based on these forecasts, analysts predict CureVac N.V. (CVAC) will achieve an average price target of $15.41.
